We are driven by the objective to develop substantially improved therapeutic options for cancer patients. Although significant progress has been achieved in recent years, many patients with late stage disease have little or no options for further treatment. We base our drug developments on latest research and international collaborations with top researchers. CatalYm is specialist in the field of innovative immune therapies and develops approaches that improve the battle of the patient’s own immune system against the cancer. We target a molecular factor called GDF-15. There is no approved drug that influences this factor so far. Our drug candidate interferes with the mechanism that regulate immune cell infiltration into tumors and that are both involved in the activation of such immune cells against cancer cells and the killing of tumor cells by those immune cells.